Cargando…
Investigators’ Experience With Expedited Safety Reports Prior to the FDA’s Final IND Safety Reporting Rule
Prior to enactment of the final investigational new drug application (IND) safety reporting rule, an attempt was made to document the effort expended at investigative sites in processing IND safety reports from sponsors and to assess the effect of these expedited reports on trial conduct. Investigat...
Autores principales: | Kramer, Judith M., Vock, David, Greenberg, Howard E., Janning, Cheri, Szczech, Lynda, Salgo, Miklos, Gagnon, Suzanne, Ellenberg, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230957/ https://www.ncbi.nlm.nih.gov/pubmed/25419504 http://dx.doi.org/10.1177/2168479013520160 |
Ejemplares similares
-
Optimizing Expedited Safety Reporting for Drugs and Biologics Subject to an
Investigational New Drug Application
por: Archdeacon, Patrick, et al.
Publicado: (2013) -
The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations
por: Wittes, Janet, et al.
Publicado: (2015) -
The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars
por: Niazi, Sarfaraz K.
Publicado: (2023) -
The effects of lobbying on the FDA’s recall classification
por: Zhou, Yifan
Publicado: (2023) -
The Food and Drug Administration’s (FDA’s) Drug Safety Surveillance During the COVID-19 Pandemic
por: Diak, Ida-Lina, et al.
Publicado: (2022)